Send to

Choose Destination
J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):87-92. doi: 10.1177/1545109709332471. Epub 2009 Mar 6.

Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.

Author information

Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.


Raltegravir (RAL) is an HIV integrase inhibitor characterized by potent antiretroviral activity, few adverse effects, and lack of cross-resistance to other antiretroviral (ARV) agents. RAL is emerging as a component of effective alternative ARV therapy for those who experience therapeutic failure or intolerance to reverse transcriptase inhibitors (NRTI and NNRTI) and ritonavir (RTV)-boosted protease inhibitor (PI) containing regimens. The combination of RAL with atazanavir (ATV) without a concomitant NRTI-based backbone or the inclusion of RTV may provide an alternative strategy for those unable to tolerate these latter ARV agents. In this report the authors present a case series of treatment-experienced patients managed with RAL + ATV given without a boosting dose of RTV. All patients tolerated this regimen over a course of 25 to 82 weeks, and had good virologic and immunologic outcome with a decrease in HIV RNA levels to <50 copies/mL and a mean CD4 count increase of 234 cells/mm(3).

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center